tiprankstipranks
Trending News
More News >
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
US Market
Advertisement

Intellia Therapeutics (NTLA) Ownership - Who Owns Intellia Therapeutics?

Compare
3,737 Followers

Intellia Therapeutics (NTLA) Ownership Overview

1.66%21.13%34.78%29.80%12.63%
34.78% Other Institutional Investors
29.80% ETFs
12.63% Public Companies and Individual Investors
The ownership structure of Intellia Therapeutics (NTLA) stock is a mix of institutional, retail, and individual investors. Approximately 85.71% of the company’s stock is owned by Institutional Investors, 1.66% is owned by Insiders, and 12.63% is owned by Public Companies and Individual Investors.
The ownership structure of Intellia Therapeutics (NTLA) stock is a mix of institutional, retail, and individual investors. Approximately 55.91% of the company’s stock is owned by Institutional Investors, 1.66% is owned by Insiders, and 29.80% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jul 25, 2025
xxxxxxxxxxxxx
$104617
Jul 03, 2025
xxxxxxxxxxxxx
$24905
Jan 07, 2025
xxxxxxxxxxxxx
$16711
Jan 07, 2025
xxxxxxxxxxxxx
$86161

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$2202086
Jun 30, 2025
xxxxxxxxxxxxx
$11434857
Jun 30, 2025
xxxxxxxxxxxxx
$25097822
Jun 30, 2025
xxxxxxxxxxxxx
$122107676

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
13,371,108Institution12.46%145,745,077
13,017,876Institution12.13%141,894,848
9,758,200Institution9.09%106,364,380
8,708,987Institution8.11%94,927,958
4,398,248Institution4.10%47,940,903
3,779,424Institution3.52%41,195,722
2,675,674Institution2.49%29,164,847
1,796,752Institution1.67%19,584,597
1,374,922Institution1.28%14,986,650
1,312,521Institution1.22%14,306,479

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
8,708,987Institution8.11%94,927,958
3,779,424Institution3.52%41,195,722
1,374,922Institution1.28%14,986,650
1,312,521Institution1.22%14,306,479
1,029,415Institution0.96%11,220,624
1,028,787Institution0.96%11,213,778
789,686Institution0.74%8,607,577
623,146Institution0.58%6,792,291
585,526Institution0.55%6,382,233
512,085Institution0.48%5,581,727

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
10,028,165Institution9.34%110,309,815
3,235,643Institution3.01%30,350,331
2,895,231Institution2.70%31,847,541
2,529,937Institution2.36%23,730,809
2,438,996Institution2.27%26,828,956
1,579,281Institution1.47%14,813,656
1,550,204Institution1.44%16,835,215
1,408,740Institution1.31%13,213,981
909,874Institution0.85%10,008,614
597,499Institution0.56%6,572,489

FAQ

Who Owns Intellia Therapeutics (NTLA)?
According to the latest TipRanks data, approximately 34.78% of the company's stock is held by institutional investors, 1.66% is held by insiders, and 12.63% is held by retail investors.
    What percentage of Intellia Therapeutics (NTLA) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 34.78% of Intellia Therapeutics (NTLA) stock is held by institutional investors.
      What percentage of Intellia Therapeutics (NTLA) stock is held by retail investors?
      According to the latest TipRanks data, approximately 12.63% of Intellia Therapeutics (NTLA) stock is held by retail investors.
        Who owns the most shares of Intellia Therapeutics (NTLA)?
        ARK owns the most shares of Intellia Therapeutics (NTLA).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis